Live Breaking News & Updates on Novel Chemical Entity

Stay updated with breaking news from Novel chemical entity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, March 27, 2024 PharmAla Biotech Holdings Inc. , a biotechnology company focused on the research,. ....

New South Wales , Nicholas Kadysh , Harpreet Kaur , Nick Kadysh , Trademark Office , Regulation Services Provider , Pharmala Biotech Holdings Inc , Neither The Canadian Securities Exchange , Drug Administration , University Of Sydney , Research At Pharmala Biotech , Novel Composition , Ala Biotech Holdings , Chemical Entity , General Population , Vice President , Novel Chemical Entity , Active Moiety , Data Exclusivity , Social Anxiety , Autism Spectrum Disorder , Orphan Indication , Intellectual Property Ontario , Canadian Securities Exchange ,

PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development - Pharmala Biotech Hldgs (OTC:MDXXF)

....

New South Wales , Harpreet Kaur , Nick Kadysh , Research Vp Dr , Trademark Office , University Of Sydney , Pharmala Biotech , Novel Chemical Entity , Benzinga Cannabis Capital , Autism Spectrum Disorder , Intellectual Property Ontario , Data Exclusivity ,

Inebriation Remedy And Breakthrough MS Treatment: Meet FSD Pharma - FSD Pharma (NASDAQ:HUGE)

Among a biotech space bursting with innovation, one company stands out as it is developing two assets at once: a ready-for-market drink that can take someone from a drinking state to mental and physical composure in record time and a potential breakthrough therapy for Multiple Sclerosis. Meet FSD Pharma (NASDAQ: ....

Zeeshan Saeed , Lakshmi Kotra , Kevin Harrington , John Duffy Jr , University Of Toronto , Breath Alcohol Concentration , Celly Nutrition , Jerry David , Shark Tank , John Duffy , Zappy Zapolin , Novel Chemical Entity ,

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Patent Filing Follows Year of Preclinical Research, Academic PublicationVANCOUVER, British Columbia, July 31, 2023 PharmAla Biotech Holdings Inc. , a biotechnology company focused on the. ....

United Kingdom , British Columbia , New South Wales , William Fantegrossi , Nicholas Kadysh , Harpreet Kaur , Nick Kadysh , Pharmala Biotech Holdings Inc , Neither The Canadian Securities Exchange , Patent Filing Follows Year Of Preclinical Research , Research For Pharmala Biotech , University Of Arkansas , University Of Windsor , University Of Sydney , Regulation Services Provider , Patent Filing Follows Year , Preclinical Research , Ala Biotech Holdings , Medical Sciences , Novel Chemical Entity , Central Nervous System , Pharmala Biotech , Ontario Centres , Spectrum Disorder , Canadian Securities Exchange ,

PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment - Pharmala Biotech Hldgs (OTC:PMBHF)

Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1.  ....

New South Wales , Nick Kadysh , William Fantegrossi , Harpreet Kaur , Sciences In Prof , University Of Windsor , University Of Arkansas , University Of Sydney , Pharmala Biotech , Novel Chemical Entity , Medical Sciences , Entactogens And Classical Psychedelics , New Published , Autism Spectrum Disorder ,